Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis

S. Peleg Hasson1,2, M. R. Brezis2, E. Shachar1,2, S. S. Shachar1,2, I. Wolf1,2 & A. Sonnenblick1,2*

1Oncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv; 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Available online xxx

Background: Approximately 50% of human epidermal growth factor receptor 2 (HER2)-positive breast cancer lesions express hormone receptors. These tumors present a unique therapeutic challenge, and the optimal endocrine therapeutic approach remains controversial. We aimed to study the optimal adjuvant endocrine therapy in this setting, to better establish the basis for clinical recommendations in HER2-positive disease.

Methods: We conducted a literature search up to May 2020, in which we identified randomized controlled trials (RCTs) that investigated the efficacy of various adjuvant hormonal therapies among premenopausal and postmenopausal patients with hormone receptor (HR)-positive, HER2-positive early breast cancer. Disease-free survival (DFS) was calculated with the random effect model and hazard ratios (HRs) with 95% confidence intervals (CI).

Results: Six RCTs (N = 5390 patients) were included in the final analysis. There was no significant difference in DFS between adjuvant treatment with aromatase inhibitors and tamoxifen (HR 0.99, 95% CI 0.68-1.44, P = 0.96). Furthermore, after omitting the ALTTO trial, as it did not randomize patients to hormonal therapy, no significant difference was observed between the two protocols (HR 1.06, 95% CI 0.65-1.73, P = 0.81).

Conclusion: Our study demonstrates similar DFS with tamoxifen and aromatase inhibitors as adjuvant endocrine treatment in HER2-positive HR-positive early-stage breast cancer patients. Future larger prospective studies focusing on the various contemporary endocrine regimens are warranted to validate our findings.

Key words: breast cancer, endocrine therapy, HER2-positive, adjuvant treatment

INTRODUCTION

Approximately 20% of breast cancers1 present with over-expression of human epidermal growth factor 2 (HER2), and 70% present with expression of hormone receptors (HR-estrogen receptor and/or progesterone receptor).2,3 HR-positive (luminal B, HER2-positive) and HR-negative (HER2-positive, non-luminal) represent two different biologic subgroups within the HER2-positive group.4 The concurrent expression of HER2 and hormone receptors may affect the natural history, response to therapy and oncologic outcomes of patients with HER2-positive early-stage breast cancer.5 Clinical outcomes differ between the two subgroups. Patients with HR-negative/HER2-positive tumors have a high risk of early relapse, while those with HR-positive/HER2-positive disease have better overall survival (OS) outcomes, and show a relatively constant annual risk of recurrence over time.6,7 Moreover, HER2-positive tumors have distinct patterns of relapse according to HR expression.8 Specifically, patients with HR-positive tumors are more likely to experience first recurrence in the bone and less likely in the brain or visceral organs compared with those with HR-negative disease.9-11 Additionally, patients with HR-positive/HER2-positive tumors have a slightly lower response to adjuvant trastuzumab compared with HR-negative/HER2-positive tumors.7

Endocrine therapy is administered for a duration of 5-10 years to patients with HR-positive early breast cancer.12-14 The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis demonstrated that aromatase inhibitors are superior to tamoxifen in reducing the risk of recurrence during years 0-4 of treatment, but not significantly thereafter.15 A 2.1% absolute improvement in 10-year breast cancer mortality was observed with the administration of aromatase inhibitors over tamoxifen.15 Recent data among premenopausal, early-stage breast cancer patients showed that aromatase inhibitors with the addition of ovarian function suppression improve disease-free survival (DFS) by approximately 4% at 8 years [hazard ratio (HR) 0.77]. There was an absolute 1% OS benefit...
among high-risk, early-stage breast cancer patients who received chemotherapy and ovarian suppression in addition to endocrine therapy with either tamoxifen or aromatase inhibitors (92.1% versus 93.3%, respectively).\textsuperscript{16}

The optimal endocrine therapy approach remains controversial in patients with HR-positive/HER2-positive disease. An analysis that included data from the ATAC, BIG 1-98 and TEAM trials in postmenopausal patients indicated that postmenopausal women with HR-positive/HER2-positive disease derive a lower benefit from the use of aromatase inhibitors over tamoxifen (HR 1.13, 95% CI 0.75-1.71) compared with those with HER2-negative tumors (HR 0.70, 95% CI 0.56-0.87). However, the small number of patients with HR-positive/HER2-positive breast cancer included in that analysis (n = 1092 across three trials) and the small number of events (n = 111) precluded strong conclusions. Additionally, trastuzumab was not available at the time for the majority of patients included in those trials.\textsuperscript{17}

Aromatase inhibitors demonstrated superiority to tamoxifen in women with HR-positive/HER2-negative disease (5.4% absolute benefit in DFS at 8 years, HR 0.70) among the population of premenopausal patients who were treated with ovarian function suppression in the SOFT/TEXT trials. However, tamoxifen resulted in a superior DFS over aromatase inhibitors (3.2% absolute benefit in DFS at 8 years, HR 1.18) among the patients with HR-positive/HER2-positive disease. Notably, a comparatively small number of patients with HR-positive/HER2-positive breast cancer (n = 695) were included in the combined two trials. Similar to the trials with postmenopausal patients, only approximately one-half of HER2-positive women included in the SOFT/TEXT trials received anti-HER2 targeted therapy.\textsuperscript{16} In a recent exploratory analysis of the ALTTO trial, the use of aromatase inhibitors was associated with reduced risk of DFS events.\textsuperscript{18}

Taken together, the evidence on the optimal regimen among the various available endocrine therapies in premenopausal and postmenopausal patients with HR-positive/HER2-positive breast cancer remains limited to validate a single optimal approach.

The objective of this systematic literature search was to consolidate and compare evidence of adjuvant endocrine therapies in this setting, to better characterize the clinical recommendations most effective for patients with HR-positive/HER2-positive disease.

**METHODS**

**Search strategy and study identification**

A systematic literature search of the Medline database and key conferences up to May 2020 was carried out independently by two authors (SPH and AS). The following keywords were used: ‘breast cancer’, ‘HER2’, ‘endocrine treatment’, ‘hormonal treatment’, ‘tamoxifen’, ‘aromatase inhibitors’, ‘letrozole’, ‘anastrozole’, and ‘exemestane’. Any discrepancies were resolved by discussion with a third author (IW). This systematic review and meta-analysis were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.\textsuperscript{19}

**Selection criteria and data extraction**

Criteria for inclusion in the meta-analysis involved eligible studies satisfying all of the following measures: (i) phase III randomized controlled trials (RCTs); (ii) RCTs including HER2 patients who received adjuvant hormonal therapy in the experimental arm; (iii) studies with available information on DFS rates in the experimental and control arms to estimate the odds ratio (OR) and 95% confidence interval (CI). Exclusion criteria were: (i) non-RCTs conducted to evaluate the role of hormonal adjuvant treatment in HER2-positive breast cancer patients; (ii) RCTs investigating hormonal treatment in patients with breast cancer subtypes other than HER2.

**Study objectives**

The primary objective of this meta-analysis was to determine the efficacy of the different available adjuvant endocrine treatment options as measured by DFS in patients with HR-positive/HER2-positive early-stage breast cancer. Two main analyses were conducted: (i) all RCTs irrespective of menopausal status or primary endpoint of the RCT trials; (ii) RCTs without inclusion of the ALTTO trial, in which the primary objective was to optimize different anti-HER2 treatments and did not randomize patients to hormonal therapy.

**Statistical analysis**

HRs and 95% CIs were calculated for the effect of different hormonal treatments in terms of DFS. Heterogeneity was observed with the $I^2$ index. Since the trials were found to be heterogenetic, a random effects model was applied, and the inverse variance-weighted method was used to calculate the CI. A funnel plot was drawn to assess publication bias. R version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria) was used for the statistical analysis.

**RESULTS**

The literature search identified 113 publications (Figure 1). Nine additional studies were identified through other sources. After the exclusion of 111 non-relevant articles, nine potentially eligible RCTs were considered,\textsuperscript{16,17,20-24} including two updates of studies that had been published earlier, leading to a final number of six RCTs for inclusion in the current meta-analysis (Figure 1).

The main characteristics of the included RCTs are listed in Table 1. All six trials were phase III RCTs, and they included a total of 35 680 patients. Overall, 5390 (15%) patients had HER2-positive disease, ranging from 6.3% (n = 389) in the BIG 1-98 trial, 10.6% (n = 178) in the ATAC trial, 11.9% (n = 366) in the SOFT trial, 12.3% (n = 525) in the TEAM trial, 12.3% (n = 329) in the TEXT trial and 100% in the ALTTO trial.

Four trials included postmenopausal patients, while the TEXT and SOFT trials\textsuperscript{16} included only premenopausal patients. In the present meta-analysis, we included only
patients from the SOFT and TEXT trials who were treated with ovarian suppression. The ALTTO trial included both premenopausal patients ($n = 1715, 47.6\%$) and postmenopausal patients ($n = 1888, 52.4\%$) with HR-positive disease; however, there were no data on ovarian suppression treatment.

---

**Table 1.** Main characteristics of the randomized controlled trials included in the present meta-analysis

| Study | Study design | Primary endpoint | Menopausal status | Treatment arms | HER2-positive patients, $n$ | Total patients, $N$ |
|-------|--------------|------------------|-------------------|---------------|-----------------------------|------------------|
| TEAM  | RCT phase III| DFS              | Postmenopausal patients | Patients randomized in a 1 : 1 ratio to receive 5 years of oral exemestane monotherapy or a sequential scheme of oral tamoxifen followed by exemestane for a total duration of 5 years<sup>a</sup> | 525 (12.3%) | 9779 |
| ATAC  | RCT phase III| DFS              | Postmenopausal patients | Patients randomized in a 1 : 1 : 1 ratio to receive anastrozole, tamoxifen or anastrozole plus tamoxifen | 178 (10.6%) | 5880 |
| BIG 1-98 | RCT phase III | DFS              | Postmenopausal patients | Patients randomized in a 1 : 1 : 1 : 1 ratio to receive monotherapy with tamoxifen or letrozole for five years or sequential therapy comprising letrozole followed by tamoxifen or vice versa<sup>b</sup> | 389 (6.3%) | 8010 |
| SOFT  | RCT phase III| DFS              | Premenopausal patients | Patients in a 1 : 1 ratio to receive tamoxifen, tamoxifen plus ovarian suppression or exemestane plus ovarian suppression for 5 years<sup>c</sup> | 366 (11.9%) | 3066 |
| TEXT  | RCT phase III| DFS              | Premenopausal patients | Patients were randomized in a 1 : 1 ratio to receive tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression for 5 years<sup>d</sup> | 329 (12.3%) | 2672 |
| ALTTO | RCT phase III| DFS              | Premenopausal patients ($n = 1715, 47.6\%$) and postmenopausal ($n = 1888, 52.4\%$)<sup>e</sup> | Patients were randomized in a 1 : 1 : 1 : 1 ratio to one of the following 1-year duration adjuvant anti-HER2 treatment arms: trastuzumab alone, lapatinib alone or trastuzumab followed by lapatinib and trastuzumab plus lapatinib<sup>f</sup> | 6273 (100%) of them | 6273 |

DFS, disease-free survival; hr, hormone receptor; RCT randomized control trial.

<sup>a</sup> The protocol was amended after the publication of the IES trial (13 December 2004). Patients assigned to tamoxifen were switched after 2.5-3.0 years to exemestane therapy for a total duration of 5.0 years of treatment.

<sup>b</sup> From 1998 to 2000, women were initially randomly assigned to receive monotherapy with letrozole (2.5 mg orally daily) or tamoxifen (20 mg orally daily) for 5 years, and later, from 1999 to 2003, they were randomly assigned to one of four arms.

<sup>c</sup> Bilateral oophorectomy or ovarian irradiation was allowed at least 6 months of receipt of triptorelin.

<sup>d</sup> As per physician’s choice, anti-HER2 treatment could be administered at the completion of chemotherapy (design 1), after anthracycline-based chemotherapy and concomitantly with a taxane (design 2), or concurrently with an anthracycline-free regimen (six cycles of docetaxel and carboplatin (i.e. Taxotere Carboplatin Herceptin)).

<sup>e</sup> Among hr-positive patients.

<sup>f</sup> Only 3603 out of 6273 included in the analysis (57.4%) were hr-positive.
All six RCTs reported the DFS outcomes. The median follow-up was 2-3 years in the ATAC, BIG1-98 and TEAM trials,8,9 8 years in the SOFT and TEXT trials10,11 and 6.9 years in the ALTTO trial.12 Analysis of all six trials included in our meta-analysis (n = 5390) revealed no significant difference between adjuvant treatment with aromatase inhibitors versus adjuvant treatment with tamoxifen (HR 0.99, 95% CI 0.68-1.44, P = 0.96; I² = 72.9%, P = 0.005) (Figure 2A). A funnel plot with pseudo 95% confidence limits (Figure 2B) demonstrated the effect of hormonal therapy estimated from individual studies (horizontal axis) against the study size (vertical axis), and it revealed that the symmetric inverted funnel shape suggested that a publication bias was unlikely. After the omission of the ALTTO trial with its different study design, analysis of the five remaining trials yielded no significant difference between adjuvant treatment with aromatase inhibitors and that with tamoxifen (HR 1.06, 95% CI 0.65-1.73, P = 0.81; I² = 71.6%, P = 0.01) (Figure 3).

DISCUSSION

Our meta-analysis included a total of 5390 women with HR-positive/HER2-positive early-stage breast cancer. The results demonstrated no difference in DFS between adjuvant endocrine treatment with aromatase inhibitors and tamoxifen.

HR-positive/HER2-positive tumors represent a unique subgroup that exhibits distinct clinical and biological behavior. Preclinical models of HR-positive/HER2-positive tumors revealed that concurrent anti-HER2 and endocrine therapy is needed to inhibit tumor growth.25,26 Clinical data demonstrated late relapses with more frequent bone involvement in HR-positive/HER2-positive tumors than in patients with HR-negative/HER2-positive disease.27,28 Suggestive of a distinctive clinical course,29,30 In the neoadjuvant setting, lower rates of pathological complete response (pCR) were reported for HR-positive/HER2-positive tumors, with a lower association between a pCR and a favorable outcome.31,32 In the NSABP B-52 trial,33 the overall pCR rates were modestly higher with the addition of endocrine therapy to chemotherapy and anti-HER2 treatment. In the metastatic setting, the PERTAIN and ALTERNATIVE trials revealed that the use of dual HER2-targeted therapy together with an aromatase inhibitor was an effective treatment strategy for HR-positive/HER2-positive metastatic breast cancer.34,35 Taken together, the preclinical and clinical data suggests the advantage of simultaneous inhibition of the HER2 and estrogen receptor signaling pathways. However, the optimal adjuvant treatment strategy for HR-positive/HER2-positive breast cancer has not yet been determined.

In the adjuvant setting, the EBCTCG meta-analysis15 demonstrated a significant reduction in recurrence of 30% during years 0-1 in HER2-positive cancers. Our analysis, that involved a longer duration of follow-up, contained premenopausal patients and included treatment with more contemporary HER2 regimens and combination therapies; we concluded that there was no difference between the regimens.

The adverse effects associated with various treatments differed between endocrine regimens. In the SOFT and TEXT trials, adverse events of grade 3 or higher were reported in more than 30% of the arms that included ovarian suppression. Thrombosis or embolism were more frequent among the tamoxifen-treated group compared with the exemestane-treated group (2.3% versus 1.2%), while musculoskeletal symptoms (11.4 versus 5.7), osteoporosis (14.8 versus 7.2%), and vaginal dryness were more frequent in the combined exemestane group. Efficacy, however, was uniform across treatment regimens, as reflected in the results of our meta-analysis of aromatase inhibitor versus tamoxifen. This finding is of major importance, freely assessing the side-effect profile to guide treatment.

We recognize that our study involves several limitations. One is the small number of HER2-positive cases across six
trials. In addition, trastuzumab treatment was not available for the majority of cases at the time of three of the trials (TEAM, ATAC and BIG 1-98). Furthermore, the TEAM, ATAC and BIG 1-98 results apply only to treatment and events occurring during the first years of treatment. Nevertheless, our study demonstrates a similar DFS among patients treated with tamoxifen versus aromatase inhibitors as adjuvant treatment in HER2-positive HR-positive early-stage breast cancer. Future larger prospective studies focusing on various endocrine regimens in this setting are warranted to validate our results.

**FUNDING**

None declared.

**DISCLOSURE**

The authors report no conflict of interest.

**REFERENCES**

1. Ferlay J, Colombo M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer*. 2019;144(8):1941-1953.
2. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. *J Natl Cancer Inst*. 2003;95(2):142-153.
3. Lai P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. *Am J Clin Pathol*. 2005;123(4):541-546.
4. Alqaisi A, Chen L, Romond E, et al. Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research. *Breast Cancer Res Treat*. 2014;148(2):437-444.
5. Schettini F, Buono G, Cardalesi C, Desideri I, De Placido S, Del Mastro L. Hormone receptor/human epidermal growth factor receptor 2-positive breast cancer: where we are now and where we are going. *Cancer Treat Rev*. 2016;46:20-26.
6. Strasser-Weippl K, Horick N, Smith IE, et al. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. *Breast Cancer Res*. 2015;17:56.
7. Untch M, Gelber RD, Jakisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. *Ann Oncol*. 2008;19(6):1090-1096.
8. Vici P, Pizzuti L, Sperti D, et al. “Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome. *Onco-target*. 2016;7(14):17932-17944.
9. Vaz-Luis I, Ottesen RA, Hughes ME, et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. *Breast Cancer Res Treat*. 2012;14(5):R129.
10. Lambertini M, Ferreira AR, Poggio F, et al. Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (neo)adjuvant trastuzumab: an Italian multicenter retrospective cohort study. *Oncology*. 2015;20(8):880-889.
11. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. *Lancet*. 2017;389(10075):1195-1205.
12. Burstein HJ, Tamin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. *J Clin Oncol*. 2014;32(21):2255-2269.
13. Cunigliano G, Burstein HJ, Winer E, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol*. 2017;28(8):1700-1712.
14. Paluch-Shimon S, Pagani O, Partridge AH, et al. ESO–ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). *Breast*. 2017;35:203-217.
15. Early Breast Cancer Trialsists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet*. 2015;386(10001):1341-1352.
16. Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. *N Engl J Med*. 2018;379(2):122-137.
17. Bartlett JMS, Ahmed I, Regan MM, et al. HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. *Eur J Cancer*. 2017;79:129-138.
18. Lambertini M, Campbell C, Gelber RD, et al. Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTT0 (BIG 2-06) randomized clinical trial. *Breast Cancer Res Treat*. 2019;177(1):103-114.
19. Moher D, Liberati A, Tetzlaff J, Altman DG, for the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PloS Med*. 2009;6(7):e1000097.
20. Ruhstaller T, Giobbie-Hurder A, Colleoni M, et al. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 trial. *J Clin Oncol*. 2019;37(2):105-114.
21. Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomized clinical trial at 8-1 median follow-up. *Lancet Oncol*. 2011;12(12):1101-1108.
22. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. *Lancet*. 2005;365(9453):60-62.
23. van de Velde CJH, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. *Lancet*. 2011;377(9762):321-331.
24. Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. *J Clin Oncol*. 2016;34(10):1034-1042.
25. Arpino G, Gutierrez C, Weiss H, et al. Treatment of human epidermal growth factor receptor-2-overexpressing breast cancer xenografts with multagent HER-targeted therapy. *J Natl Cancer Inst*. 2007;99(9):694-705.
26. Rimawi MF, Wiechmann LS, Wang Y-C, et al. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu overexpressing breast tumor xenografts. *Clin Cancer Res*. 2011;17(6):1351-1361.
27. Vici P, Pizzuti L, Natoli C, et al. Triple positive breast cancer: a distinct subtype? *Cancer Treat Rev*. 2015;41(2):69-76.
28. Park YH, Lee S, Cho EY, et al. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. *Cancer Chemother Pharmacol*. 2010;66(3):507-516.
29. Schaff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. *Clin Cancer Res*. 2004;10(1 Pt 2):331S-336S.
30. Bender LM, Nahta R. HER2 cross talk and therapeutic resistance in breast cancer. *Front Biochem*. 2008;13:3906-3912.
31. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CNeoBC pooled analysis. *Lancet*. 2014;384(9938):164-172.
32. von Minckwitz G, Untch M, Blomher J-U, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant
33. Rimawi M, Cecchini R, Rastogi P, et al. Abstract S3-06: a phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52. Cancer Res. 2017;77. S3-06.

34. Rimawi M, Ferrero J-M, de la Haba-Rodriguez J, et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol. 2018;36(28):2826-2835.

35. Johnston SRD, Hegg R, Im S-A, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in post-menopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE. J Clin Oncol. 2018;36(8):741-748.